| Breast Cancer |
1 |
1 |
| Biologic Therapy |
0 |
0.95 |
| Cancer |
0 |
0.79 |
| Antineoplastic Drug |
0 |
0.69 |
| Toxicology |
0 |
0.52 |
| Breast |
0 |
0.33 |
| Tumor |
0 |
0.21 |
| Antibody Drug Conjugates |
0 |
0.17 |
| Chemotherapy |
0 |
0.17 |
| Hodgkin Lymphoma |
0 |
0.17 |
| Receptors |
0 |
0.17 |
| Antigens |
0 |
0.13 |
| Humanized Monoclonal Antibody |
0 |
0.13 |
| Neoadjuvant Therapy |
0 |
0.13 |
| Polymerase Chain Reaction |
0 |
0.13 |
| Surgery |
0 |
0.13 |
| Cardiomyopathy |
0 |
0.09 |
| Endocrine Therapy |
0 |
0.08 |
| Hospital |
0 |
0.08 |
| Massachusetts |
0 |
0.08 |
| Neuropathy |
0 |
0.08 |
| Translational Research |
0 |
0.08 |
| Tyrosine Kinase Inhibitor |
0 |
0.06 |
| Anthracyclines |
0 |
0.04 |
| Biomarker |
0 |
0.04 |
| Board Certification |
0 |
0.04 |
| Estrogen |
0 |
0.04 |
| Hormonal Therapy |
0 |
0.04 |
| Immunohistochemistry |
0 |
0.04 |
| Leukemia |
0 |
0.04 |
| Myelosuppression |
0 |
0.04 |
| Residual Disease |
0 |
0.04 |
| Taxane |
0 |
0.04 |
| Texas |
0 |
0.04 |
| Tyrosine Kinase |
0 |
0.04 |